{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:48:33Z","timestamp":1762955313171},"reference-count":62,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2014,7,1]]},"DOI":"10.1586\/14787210.2014.919852","type":"journal-article","created":{"date-parts":[[2014,5,22]],"date-time":"2014-05-22T10:55:08Z","timestamp":1400756108000},"page":"743-752","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Efinaconazole (Jublia) for the treatment of onychomycosis"],"prefix":"10.1586","volume":"12","author":[{"given":"Aditya K","family":"Gupta","sequence":"first","affiliation":[{"name":"Mediprobe Research Inc.,\r645 Windermere Rd., London, ON, Canada"},{"name":"Department of Medicine, University of Toronto,\rToronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona C","family":"Simpson","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc.,\r645 Windermere Rd., London, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,5,22]]},"reference":[{"key":"CIT0001","author":"Sigurgeirsson B","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1972.01620050069017"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.02.038"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2009.12.006"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200001010-00002"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12122"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2010.07.008"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02464.x"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2000.00012.x"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2000.00124.x"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1159\/000018174"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.4274\/turkderm.00908"},{"key":"CIT0013","unstructured":"Valeant. Penlac\u00ae Nail Lacquer (ciclopirox) Topical Solution, 8% [Internet]. Q www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/21022s004lbl.pdf"},{"key":"CIT0014","unstructured":"Medicines and Healthcare products Regulatory Agency. Public Assessment Report Decentralised Procedure Amorolfine 5% W\/V Nail Lacquer. 2011. Available from: www.mhra.gov.uk\/home\/groups\/par\/documents\/websiteresources\/con129125.pdf"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1517\/17425240802497218"},{"key":"CIT0016","unstructured":"Novartis. LAMISIL (terbinafine hydrochloride) Tablets, 250 mg [Internet]. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020539s021lbl.pdf"},{"key":"CIT0017","volume-title":"Treatment of skin disease","author":"Tosti A","year":"2014","edition":"4"},{"key":"CIT0018","unstructured":"Janssen Pharma. SPORANOX\u00ae (itraconazole) Capsules [Internet]. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020083s048s049s050lbl.pdf"},{"issue":"3","key":"CIT0019","first-page":"47","volume":"12","author":"Casciano J","year":"2003","journal-title":"Manag Care Langhorne Pa"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1159\/000018488"},{"key":"CIT0021","unstructured":"Penlac, ciclopirox (topical solution 8% w\/w). Product monograph. Health Can Prod Drug Data Base Val Can. 2012"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.109071"},{"key":"CIT0023","unstructured":"AMYCOR ONYCHOSET, pomade. 1994.Available from: http:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=67886607#Presentations"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1997.00024.x"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.10.013"},{"key":"CIT0026","unstructured":"Elewski BE, Rich P, Wiltz H, et al. Effectiveness and safety of tavaborole, a novel boron-based molecule for the treatment of onychomycosis: results from two phase 3 studies. 2013.Available from: http:\/\/anacor.com\/pdf\/Tavaborole_Phase%203%20Poster_Final%20Copy_093013.pdf"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12168"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.711315"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00158-11"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.47.1417"},{"key":"CIT0031","unstructured":"United States Adopted Names Council. Statement on a nonproprietary name adopted by the USAN Council: Efinaconazole. Available from: www.ama-assn.org\/resources\/doc\/usan\/efinaconazole.pdf"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02063-12"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02056-12"},{"issue":"4","key":"CIT0034","first-page":"AB110","volume":"68","author":"Sugiura K","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"CIT0035","first-page":"AB104","volume":"68","author":"Bhatt V","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"CIT0036","unstructured":"Valeant Canada LP. PrJUBLIATM Efinaconazole Topical Solution, 10% w\/w. 2013"},{"issue":"9","key":"CIT0037","first-page":"1010","volume":"12","author":"Jarratt M","year":"2013","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"CIT0038","first-page":"186","volume":"12","author":"Tschen EH","year":"2013","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"CIT0039","first-page":"20","volume":"6","author":"Del Rosso JQ","year":"2013","journal-title":"J Clin Aesthetic Dermatol"},{"key":"CIT0040","unstructured":"Valeant Pharmaceuticals Inc. Valeant Pharmaceuticals Announces Approval Of Jublia\u00ae For The Treatment Of Onychomycosis In Canada. 2013. Available from: http:\/\/ir.valeant.com\/investor-relations\/news-releases\/news-release-details\/2013\/Valeant-Pharmaceuticals-Announces-Approval-Of-Jublia-For-The-Treatment-Of-Onychomycosis-In-Canada\/default.aspx"},{"key":"CIT0041","unstructured":"Valeant Pharmaceuticals. Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole. 2013. Available from: http:\/\/ir.valeant.com\/investor-relations\/news-releases\/news-release-details\/2013\/Valeant-Pharmaceuticals-Announces-Receipt-Of-US-FDA-Complete-Response-Letter-For-Efinaconazole\/default.aspx"},{"key":"CIT0042","author":"Gupta AK","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1080\/09546630701657187"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2013.06.011"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2006.00054"},{"issue":"3","key":"CIT0046","first-page":"302","volume":"4","author":"Gupta AK","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.04.062"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.149.s65.5.x"},{"key":"CIT0049","unstructured":"Flack M, Robinson P, Ijzerman M, Baker J Jr. Efficacy of topical nanoemulsion (NB-002) for the treatment of distal subungual onychomycosis: a randomized, double-blind, vehicle-controlled trial. Miami Beach, Florida; 2010. Available from: www.nanobio.com\/News\/documents\/2010_AAD_P2108.pdf [Last accessed 11 April 2013]"},{"key":"CIT0050","unstructured":"Glaxo-Smith Kline. A phase 2, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in subjects with distal subungual onychomycosis. 2012. Available from: www.gsk-clinicalstudyregister.com\/result_detail.jsp?protocolId=114554&studyId=4ED3A7C8-ABAF-4DC7-B1A4-362C64C27D09&compound=albaconazole&type=Compound&letterrange=A-F"},{"key":"CIT0051","unstructured":"Topica Pharmaceuticals. Safety and efficacy of luliconazole solution, 10% in subjects with mild to moderate onychomycosis - full text view - ClinicalTrials.gov. ClinicalTrials.gov. 2011. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01431820"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.3109\/13693780903373811"},{"key":"CIT0053","unstructured":"Pinpointe USA. 510(k) Summary K093547. PinPointe FootLaser, Pinpointe USA Inc. 2010. Available from: www.accessdata.fda.gov\/cdrh_docs\/pdf9\/K093547.pdf"},{"key":"CIT0054","unstructured":"Cutera Inc. 510(k) Summary K103626. GenesisPlus, Cutera Inc. 2011. Available from: www.accessdata.fda.gov\/cdrh_docs\/pdf10\/K103626.pdf"},{"key":"CIT0055","unstructured":"Light Age Inc. 510(k) Summary K110370. Q-Clear, Light Age. 2011. Available from: www.accessdata.fda.gov\/cdrh_docs\/pdf11\/K110370.pdf"},{"key":"CIT0056","unstructured":"Alma Lasers. 510(k) Summary K113810. Harmony, Alma Lasers Inc. 2012. Available from: www.accessdata.fda.gov\/cdrh_docs\/pdf11\/K113810.pdf"},{"key":"CIT0057","unstructured":"Sciton Inc. 510(k) Summary K111483. JOULE ClearSense, Sciton Inc. 2011. Available from: www.accessdata.fda.gov\/cdrh_docs\/pdf11\/K111483.pdf"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.1080\/13693780701836977"},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-1097.2010.00848.x"},{"key":"CIT0060","unstructured":"A dose-ranging study evaluating the safety and efficacy of IDP-108 in patients with onychomycosis. Available from: www.clinicaltrials.gov\/ct2\/show\/NCT00777868"},{"key":"CIT0061","unstructured":"Safety and efficacy of topical IDP-108 versus vehicle in patients with onychomycosis. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01008033"},{"key":"CIT0062","unstructured":"The safety and efficacy of topical IDP-108 versus vehicle in patients with onychomycosis. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01007708"}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/14787210.2014.919852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T23:24:45Z","timestamp":1598743485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1586\/14787210.2014.919852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,22]]},"references-count":62,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7,1]]}},"alternative-id":["10.1586\/14787210.2014.919852"],"URL":"https:\/\/doi.org\/10.1586\/14787210.2014.919852","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"value":"1478-7210","type":"print"},{"value":"1744-8336","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-06-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}